Abstract
In this high-HIV-prevalence and drug-resistant TB setting, a history of prolonged hospitalization and previous TB treatment failure were strong risk factors for both MDR and XDR-TB. Given high mortality observed among patients with HIV and drug-resistant TB co-infection, previously treated and hospitalized patients should be considered for empiric second-line TB therapy while awaiting confirmatory DST results in settings with a high-burden of MDR/XDR-TB.
Introduction
The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) represents a significant threat to global health, particularly in regions with high HIV prevalence. In these settings, the standard diagnostic process—relying on culture-based drug-susceptibility testing (DST)—presents a critical bottleneck. The 6–8 week turnaround time for results often exceeds the survival time of co-infected patients. This "diagnostic gap" necessitates the identification of clinical predictors that can guide immediate, empiric treatment decisions.
Methods
This study utilized a retrospective case-control design to identify risk factors for drug-resistant TB in Tugela Ferry, South Africa. The study population consisted of 378 patients categorized into three groups: drug-susceptible TB (n=116), MDR-TB (n=123), and XDR-TB (n=139). Data were sourced from the Church of Scotland Hospital (COSH) records and provincial laboratory results between 2005 and 2007. Multivariate logistic regression was employed to determine adjusted odds ratios (aOR) for various demographic and clinical factors, controlling for potential confounders.
Key Findings
The Impact of Previous Treatment Failure
The most significant predictor identified was a history of TB treatment failure. Patients who had previously failed a TB regimen were over 50 times more likely to present with MDR-TB (aOR 51.7) or XDR-TB (aOR 51.5) compared to those with drug-susceptible strains. This highlights a critical cohort for whom standard first-line therapy is likely to be ineffective.
Hospitalization and Nosocomial Transmission
Prolonged hospitalization (defined as >14 days in the preceding year) emerged as a substantial risk factor, increasing the odds of MDR-TB by 3.8 times and XDR-TB by 6.1 times. Notably, "defaulting" from previous treatment (starting but not finishing a course) was not a significant predictor in this setting. This suggests that the epidemic in Tugela Ferry is driven largely by primary transmission—often within healthcare facilities—rather than the acquisition of resistance through poor individual adherence.
HIV and XDR-TB Susceptibility
While HIV prevalence was high across all study groups (>85%), HIV infection was specifically associated with a higher risk of XDR-TB (aOR 8.2) compared to MDR-TB. This suggests that HIV-positive individuals may be uniquely vulnerable to the most resistant strains or are more frequently exposed to them in high-risk environments.
Clinical Implications and Conclusion
The findings underscore the urgent need for rapid molecular diagnostics to replace slow culture-based methods. However, in the absence of such technology, clinical markers like previous treatment failure and recent hospitalization should serve as "red flags."
In high-burden settings, clinicians should consider initiating empiric second-line therapy for patients meeting these criteria while awaiting laboratory confirmation. Furthermore, the link between hospitalization and resistance emphasizes the necessity of rigorous hospital infection control measures to prevent healthcare facilities from becoming epicenters of drug-resistant TB transmission.
Limitations
The study's retrospective nature and hospital-based setting may introduce selection bias. Additionally, certain social determinants (e.g., homelessness, incarceration) were not captured in the available records. Despite these limitations, the identified predictors offer a practical framework for risk stratification in resource-limited, high-HIV settings.
Summary updated